Sophoridine

SKU: orb1223076

Description

Sophoridine, a natural anticancer drug, has been used in China for decades. A series of novel N-substituted Sophoridinic acid derivatives were synthesized and evaluated for their cytotoxicity with 1 as the lead. The structure-activity relationship indicated that introduction of an aliphatic acyl on the nitrogen atom might significantly enhance the anticancer activity. Among the compounds, 6b bearing bromoacetyl side-chain afforded a potential effect against four human tumor cell lines (liver, colon, breast, and lung). The mechanism of action of 6b is to inhibit the activity of DNA topoisomerase I, followed by the S-phase arrest and then cause apoptotic cell death, similar to that of its parent 1.(In Vitro):Sophoridine (0-500 μM; 48 hours) exhibits remarkable inhibition effects to the growth of human pancreatic, gastric, liver, colon, gallbladder, and prostate carcinoma cells with IC50 values of about 20 μM to 200 μM.Sophoridine (0-20 μM; 48 hours) increases S phase cell population from 26.23% (control) to 38.67% in Miapaca-2 cells and from 29.56% (control) to 39.16% in PANC-1 cells, about a 1.5-fold and a 1.3-fold increase, respectively.Sophoridine (0-20 μM; 48 hours) significantly increases bad and bax levels, and decreases bcl-2 and bcl-xl levels in contrast, with a significant increase in Bax/Bcl-2 ratio.(In Vivo):Sophoridine (intraperitoneal injection; 20 or 40 mg/kg; 21 days) can inhibit the growth of xenograft pancreatic tumors.

Key Properties

• CAS Number: 6882-68-4
• MW: 248.36
• Purity: >98% (HPLC)
• Formula: C₁₅H₂₄N₂O
• SMILES: C1C[C@@H]2[C@H]3CCCN4[C@H]3[C@H](CCC4)CN2C(=O)C1
• Target: Beta Amyloid
• Solubility: In Vitro: DMSO : 50 mg/mL (201.32 mM)

Bioactivity

• In Vivo:
  Sophoridine (intraperitoneal injection; 20 or 40 mg/kg; 21 days) can inhibit the growth of xenograft pancreatic tumors. Animal model: BALB/c homozygous (nu/nu) nude mice. Dosage: 20 or 40 mg/kg. Administration: Intraperitoneal injection; 20 or 40 mg/kg; 21 days. Result: Decreased xenograft pancreatic tumors mass.
  Read more...
• In Vitro:
  Sophoridine (0-500 μM; 48 hours) exhibits remarkable inhibition effects to the growth of human pancreatic, gastric, liver, colon, gallbladder, and prostate carcinoma cells with IC50 values of about 20 μM to 200 μM. Sophoridine (0-20 μM; 48 hours) increases S phase cell population from 26.23% (control) to 38.67% in Miapaca-2 cells and from 29.56% (control) to 39.16% in PANC-1 cells, about a 1.5-fold and a 1.3-fold increase, respectively. Sophoridine (0-20 μM; 48 hours) significantly increases bad and bax levels, and decreases bcl-2 and bcl-xl levels in contrast, with a significant increase in Bax/Bcl-2 ratio. Cell Viability Assay Cell line: Normal cells: IOSE144, HL-7702 and LO2, BEAS-2B, GES-1, HEK 293 T, HPDE, FHC, Human cancer cells: PANC-1, Mapaca-1, hepG2, SGC-7901, CBC-SD, SGC-996, PC-3, MKN-45, MGC-803, Hela and HCT116 cells. Concentration: 0, 3.9, 7.8, 15.5, 31, 62.5, 125, 250, 500 μM Incubation time: 48 hours. Result: Exhibited the most potent cytotoxicity to cancer cells. Cell Cycle Analysis Cell line: PANC-1 cells; Miapca-2 cells. Concentration: 20 μM. Incubation time: 48 hours. Result: Led to accumulated population in the S phase. Western blot analysis. Cell line: PANC-1 cells; Miapca-2 cells. Concentration: 20 μM. Incubation time: 48 hours. Result: Inducedthe activation of intrinsic apoptosis pathway.
  Read more...

Storage & Handling

• Storage: Storage temperature: -20°C. Stability: ≥ 2 years
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Quick Database Links

Gene Symbol

Beta Amyloid